After doxorubicin treatment, Shc3 overexpression group tumor volume reduced 34.50% compared with doxorubicin untreatment MCF‐7/ADR‐Shc3 group; control group tumor volume reduced 66.95% compared with doxorubicin untreatment MCF‐7/ADR‐Vector group. This evidence concerns the gene SHC3 and neoplasm.